Carlsmed (CARL) Net Income towards Common Stockholders (2024 - 2026)

Carlsmed (CARL) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$10.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 55.34% year-over-year to -$10.5 million; the trailing twelve-month figure through Jun 2026 stood at -$36.3 million (down 38.7% YoY), and the FY2025 full-year result was -$30.2 million, down 21.61% from the prior year.
• Net Income towards Common Stockholders eased to -$10.5 million in Q2 2026 per CARL's latest filing, from -$8.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$4.7 million in Q4 2024 and bottomed at -$10.5 million in Q2 2026.
• Historically, Net Income towards Common Stockholders has averaged -$7.6 million across 3 years, with a median of -$8.4 million in 2024.
• The widest YoY moves for Net Income towards Common Stockholders: up 1.44% in 2025, down 82.48% in 2025.
• Over 3 years, Net Income towards Common Stockholders stood at -$4.7 million in 2024, then tumbled by 82.48% to -$8.6 million in 2025, then declined by 22.02% to -$10.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$10.5 million, -$8.7 million, and -$8.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.